Monofer (Ferric Derisomaltose)

Ferric Derisomaltose delivers a stable iron‑carbohydrate complex that releases bioavailable iron after IV infusion. The iron is captured by reticuloendothelial cells, transferred to transferrin, and incorporated into hemoglobin, thereby restoring normal red blood cell production.

The dose of Monofer is individualized by the prescribing clinician based on the patient’s iron deficit, body weight, and clinical condition. The prescriber determines the total iron requirement and the infusion schedule, which is administered intravenously under medical supervision.

Safety data for Monofer in pregnancy and lactation are limited. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To order Monofer, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where needed) and import documentation.

Monofer (ferric derisomaltose) offers a high‑dose, single‑visit infusion option, whereas iron sucrose typically requires multiple smaller doses. Compared with ferric carboxymaltose, Monofer has a similar safety profile but may differ in infusion time and maximum single‑dose limits, influencing choice based on patient needs and clinical setting.

Monofer must be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and do not freeze or shake the solution. If the product reaches room temperature, it should be used promptly and not re‑refrigerated.

Monofer is given as an intravenous infusion by a qualified healthcare professional. The vial is diluted according to the manufacturer’s instructions and infused over a period that may range from a few minutes to several hours, depending on the prescribed dose and patient tolerance.

Serious risks include anaphylactic reactions, severe hypotension, acute respiratory distress, iron overload, and rare cardiac events. Patients should be monitored closely during and after the infusion for any signs of these reactions, and emergency measures should be readily available.

Monofer is contraindicated in individuals with known hypersensitivity to ferric derisomaltose or any component of the formulation, as well as in patients with active systemic infections or severe uncontrolled hypertension. Caution is also advised for those with severe renal impairment or a history of severe allergic reactions to IV iron.